Received Apr 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 74NC9 | — |
Late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 69-year-old female patient who received Herpes zoster (Shingrix) (batch number 74NC9, expiry date 13-NOV-2026) for prophylaxis. Previously administered products included Shingrix (Patient had first dose in 30-AUG-2023 with batch number 2GG34 and expiry date 21-AUG-2024). On 09-JAN-2025, the patient received the 2nd dose of Shingrix. On 09-JAN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 27-MAR-2025 Patient got their first dose of Shingrix on August 30th 2023 and a late second dose on January 9th 2025, and patient was recommended to restart the series. Patient did not tell her anything about being immunocompromised. The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccinations schedule.